In the third quarter, the company achieved gross revenue growth of 10 per cent and net revenue growth of 5 per cent, reflecting steady momentum across both OTC and ETC channels. Cost of goods sold rose by only 3 per cent, supported by efficient production planning, higher factory utilization, and proactive cost optimization across four factory clusters. The company also commissioned its final lyophilized powder line at the EU-GMP IMP4 facility, further expanding capacity.
Gross profit increased 9 per cent year-on-year, maintaining a stable gross margin of 40 per cent. Selling, general and administrative expenses grew by only 3 per cent, underscoring disciplined cost control amid continued investment in market expansion and digital transformation.
Imexpharm’s IMP4 plant meets EU-GMP standards. Photo: Imexpharm.
Profit before tax rose 11 per cent year-on-year, while EBITDA increased 12 per cent, highlighting the company’s ongoing focus on profitability and operational efficiency. After a soft August, sales rebounded sharply in September, with net revenue up 25 per cent month-on-month, profit before tax up 101 per cent, and EBITDA up 48 per cent.
For the first nine months of 2025, Imexpharm achieved robust growth across all key metrics. Gross revenue reached VND 2,118 billion (approximately USD 82 million), up 21 per cent year-on-year, while net revenue grew 16 per cent. OTC and ETC channels expanded 19 per cent and 21 per cent respectively. Gross profit climbed 21 per cent, profit before tax 23 per cent, and EBITDA 18 per cent. The gross margin remained at 40 per cent, with EBITDA margin improving to 22.3 per cent.
The product quality inspection line at Imexpharm’s IMP4 plant. Photo: Imexpharm.
By the end of September, Imexpharm had achieved 68 per cent of its full-year net revenue target and 63 per cent of its profit-before-tax goal. The company launched 20 new SKUs, exceeding its annual plan of 16, and maintained a strong innovation pipeline with 144 R&D projects under development.
According to a board resolution dated September 23, 2025, Imexpharm has proposed issuing more than 1.55 million ESOP shares at VND 5,000 (approximately USD 0.20) each, subject to shareholder approval via written ballot. The shares will carry a one-year transfer restriction after the offering. As of September 30, 2025, Imexpharm’s share price had risen 14 per cent since the beginning of the year.